REGISTER BY 7TH DECEMBER AND RECEIVE A £300 DISCOUNT REGISTER BY 18TH JANUARY AND RECEIVE A £200 DISCOUNT

SMi present their 9th annual conference on...

Imaging in Cancer Drug Development Clinical Application and Innovation 13th and 14th March 2013, Copthorne Tara Hotel, London, UK KEY SPEAKERS INCLUDE: Anthony Giamis

Prash Krishna

Head of Radiochemistry Abbott

Director – Oncology Clinical Development Eisai

Peter Eggleton

Yanping Luo

Medical Director Oncology Merck

Group Leader, Translational Imaging Abbott

Werner Scheuer

Kevin Brindle

Research Leader Preclinical Imaging; Pharma Research and Early Development Roche

Professor of Biomedical Magnetic Resonance Cambridge University

Francois Lasailly

Laura Kenny

In-vivo Imaging Specialist Cancer Research UK

Clinical Senior Lecturer/Consultant in Medical Oncology Imperial College

Albert Windhorst Head of Radiopharmaceutical Chemistry VU University

Erik Arstad Senior Lecturer in Radiochemistry UCL

Janos Kriston-Vizi Group Leader of Bioinformatics Image Core Medical Research Council

Teng Jin Ong Global Clinical Leader in Oncology Bayer

KEY TOPICS FOR 2013: Sponsored by

• Latest developments in fluorescence and bioluminescence for drug monitoring in xenografts • Novel target identification and lead discovery in preclinical biomarkers and radiochemistry • Strengths and limitations of whole body optical imaging with X-ray micro CT and multiphoton intravital microscopy • Overcoming challenges in nuclear tracers for multiscale imaging in oncology • Current application of PET/SPET modalities and a review of PFS (progression-free survival) • Practical tools for business expansion in the current economic climate

PLUS INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOP Tuesday 12th March 2013, Copthorne Tara, London, UK

Development of radiopharmaceuticals for PET Imaging in Oncology Workshop Leader: Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU University 13.00 – 17.00

TO BOOK Visit www.cancer-imaging.com Register online and receive full information on all of SMi’s conferences Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

Imaging in Cancer Drug Development 2013

www.cancer-

Day One | Wednesday 13th March 2013

08.30

Registration and Coffee

CURRENT ROLE OF IMAGING MODALITIES

09.00

Chairman's Opening Remarks Peter Eggleton, Medical Director Oncology, Merck

09.10

Application of in vivo and ex vivo imaging in the drug development process: monitoring primary tumor growth, metastasis and angiogenesis • Application of fluorescence and bioluminescence for drug monitoring in xenografts • Monitoring primary tumor growth, metastasis and angiogenesis • Simultaneous measurement of pharmacodynamics and pharmacokinetics • Future aspects (Cerenkov and hybrid systems) Werner Scheuer, Principle Optical Imaging, Roche

09.50

Novel advances in molecular imaging using the PhotonIMAGER OPTIMA system • Novel targets • Compare and contrast analogues • Challenges faced with novel targets • Future developments Nicolas Carvou, Application Scientist, Biospace Lab

10.30

Morning Refreshments

13.40

Watching tumours gasp and die with MRI • Early detection of treatment response - why and how • Imaging tumour metabolism with hyperpolarised 13C-labelled cell substrates • Detecting drug response • Detecting tumour cell death • Imaging the tumour microenvironment Kevin Brindle, Professor of Biomedical Magnetic Resonance, Cambridge University

14.20

Current role of PET/CT in cancer imaging – hybrid imaging improves the assessment of bone metastasis • The skeleton is a common site for metastases and newer treatment are under investigation • Bone metastases are usually considered “non-measurable” • Hybrid imaging provides new insight in the assessment of bone metastases Yong Du, Consultant in Nuclear Medicine and PET/CT, Royal Marsden Hospital

15.00

Afternoon Tea QUANTITIVE STUDIES & CHANGING PERSPECTIVES

PRE-CLINICAL & CLINICAL IMAGING 15.30

Quantitative in vivo imaging of disease and response to therapy • Promise and peril of in vivo imaging • FRAP of eCadherin to study EMT • Sub-cellular targeting of Rho • Spatial and temporal dynamics of Src response Kurt Anderson, Oncology Team Leader, The Beatson Institute for Cancer Research

Overcoming chemical challenges in radiotracer development • Synthesis of dual optical and nuclear tracers for multiscale imaging • Preparation of functional nanoparticles for imaging with SPECT and MRI • One-pot ‘click-labelling’ of chemically labile precursors • 18F aromatic labelling of ‘drug-like’ tracers Erik Arstad, Senior Lecturer in Radiochemistry, UCL

16.10

Independent Radiological Committe (IRC) review for PFS - revisited • IRC and its role in oncology drug development • IRC versus Inv led Reviews • Changing Perspectives Prash Krishna, Director – Oncology, Clinical Development, Eisai

16.50

Chairman’s closing remarks

Networking Lunch

17.00

Close of day one

11.00

Non-invasive imaging of pre-clinical models for basic translational research • Whole body optical imaging (bioluminescence and NIR fluorescence), X-ray micro CT and multiphoton intravital microscopy • Strengths and limitations • Ongoing developments Francois Lasailly, In-vivo Imaging Specialist, Cancer Research UK

11.40

12.20

Register online at www.cancer-imaging.com • Alternatively fax yo Sponsored by

SPONSORSHIP AND EXHIBITION OPPORTUNITIES Biospace Lab’s range of instruments is dedicated to small animal preclinical imaging. Biospace Lab has developed a comprehensive portfolio of ex vivo, in vivo and now in actio imaging solutions; which are used by almost every major pharmaceutical company and prestigious academic research institutes worldwide. www.biospacelab.com

Supported by

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: [email protected]

-imaging.com

Day Two | Thursday 14th March 2013

8.30

Re-registration and Coffee

09.00

Chairman's Opening Remarks Anthony Giamis, Head of Radiochemistry, Abbott

12.10

Improving medical imaging diagnoses • High quality display and graphics for improved diagnostic abilities and patient treatment • Explore advancements in diagnoses solutions • Developments in software platforms for imaging in cancer drug discovery • Innovative multi-display technology – increase number of reviews per day Yanping Luo, Group Leader, Translational Imaging, Abbott

12.50

Networking Lunch

14.20

Imaging modalities in drug discovery: high-content screening of a kinase inhibitor small molecule library to identify autophagy regulators • Imaging modalities incorporating kinase inhibitors • Identifying autophagy regulators • Challenges faced in HTS of kinase inhibitors • Future developments Janos Kriston-Vizi, Group Leader of Bioinformatics Image Core, Medical Research Council

15.10

Afternoon Tea

IMAGING BIOMARKERS IN CANCER DRUG DEVELOPMENT 09.10

PET/SPECT imaging biomarker development • Target identification and lead finding • Radiochemistry aspects • Preclinical evaluation • Translation towards clinic Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU University

09.50

The importance of efficient early detection and diagnosis • Observing tumor location(s), tumor-associated neoangiogenesis, suppression of antitumor immunity and visualising expression • Activity of specific molecules and biological processes that influence tumor behaviour and response to therapy • Impact on cancer detection, metastases classification, individualized treatment, and drug development • Bioluminescence and photoacoustic imaging applications Teng Jin Ong, Global Clinical Leader in Oncology, Bayer

10.30

Biomarkers as predictors of therapeutic efficacy • Image-guided therapeutic delivery - development of novel cancer imaging probes and biomarkers for screening, detection, diagnosis • Utilization of biomarkers for effective patient enrolment and proficient exchange of treatment paradigms – financial savings in the pharmaceutical industry • Role of imaging biomarkers in distinguishing metastases – efficient prognosis • Biomarkers and individualised medicine Laura Kenny, Clinical Senior Lecturer/Consultant in Medical Oncology, Imperial College

11.00

FUTURE OF IMAGING IN CANCER DRUG DEVELOPMENT 15.50

Outmanagement for imaging experts in cancer drug development • Practical tools for survival and growth during a period of retrenchment • Expansion of medical imaging products in the market • Managing practical issues associated with oncology imaging • Standardization and development of proficiency in the field Peter Eggleton, Medical Director Oncology, Merck

16.30

The pricing and reimbursement environment • Key changes to payers willingness to pay • The cost containment programmes in key markets • How to ‘prove’ Value Brian Lovatt, CEO, Vision Healthcare

17.10

Chairman’s closing remarks

17.20

Close of day two

Morning Refreshments IMPROVING SUCCESS OF IMAGING MODALITIES

11.30

Molecular imaging innovation: PET/SPECT imaging in translational science • Choosing a Target or Mechanism • Preparation of Radiotracer • Imaging Translation • Outcome and Assessments Anthony Giamis, Head of Radiochemistry, Abbott Laboratories

our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Who should attend this conference: You should attend this event if you are a Director, Area Head, Chief Executive, Chief Scientific Officer, Vice President, Heads, Principal Scientist or Manager within the Pharmaceutical or Healthcare industry with responsibilities in the following areas: • Imaging and Translational Medicine • Molecular Imaging • Cancer Research • Oncology • Pre-clinical Imaging • Clinical Imaging

• PET Research • Biomarkers • Target Discovery • Pharmacokinetics/ Pharmacodynamics • Drug Discovery & Design

• Computer-Aided Drug Design • Computational Chemistry • Structure and Informatics • Molecular Interaction

• Medical Imaging • Clinical Pharmacology • Biophysics • Screening • Clinical Development • Structural Biology

Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Contact Kellee Halliburton, SMi Marketing on +44 (0) 207 827 6194, or email [email protected]

HALF-DAY PRE-CONFERENCE WORKSHOP Tuesday 12th March 2013 13.00 – 17.00 Copthorne Tara Hotel, London, UK

Development of radiopharmaceuticals for PET Imaging in Oncology In association with

VU University Workshop Leader: Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU University Overview of workshop: This workshop will be a unique interactive session where attendees can explore the development of radiopharmaceuticals for PET Imaging in Oncology, alongside emerging ideas and case studies that can be applied to their own roles and environments. Led by the expertise and experience of Albert Windhorst, of VU University, the workshop will explore the treatment of patients early in their disease process and facilitate the understanding of unmet needs in cancer drug development and oncology imaging. Overview of workshop: • Discover the benefits of developing radiopharmaceuticals for PET Imaging in oncology research • Address and overcome the key challenges associated with developing radiopharmaceuticals for PET Imaging • Evaluate past experiences and case studies and benefit from lessons learnt • Engage in an interactive session with a unique platform for discussion Workshop Agenda: 13.00 Registration and coffee 13.30

Welcome & Introductions

13.40

Route from conceptual idea to human application of a PET radiopharmaceutical • Identify biological targets for imaging • Identify lead compounds for radiopharmaceutical development

14.15

Small molecule PET tracer development and monoclonal antibody PET tracers • Nuclides and radiochemistry • Considerations for development

15.15

Afternoon Break

15.30

Translation from preclinical research to clinical research • Animal experiments and typical studies • GMP production and legislation

16.30

Discussion Session

17.00

Close of Workshop

About the workshop host Dr Windhorst currently holds a position as associate professor in radiopharmaceutical chemistry at the VU University Medical Center, where he heads the radiopharmaceutical chemistry section of the department of Nuclear Medicine & PET Research. His main research interest is in the development and production of 11C and 18F radiolabeled compounds for clinical PET imaging, both research as for routine applications. He is member of the board of the NKRV, EANM Drug Development committee, president elect of the SRS, chairman of the 19th International Symposium on Radiopharmaceutical Chemistry, member of the scientific advisory board of the Journal Labeled Compounds and Radiopharmaceuticals and of Current Radiopharmaceuticals. About VU University Research at VU University Amsterdam covers a wide range of fields that often cut across disciplinary boundaries. Within the Radionuclide Centre (RNC) scientific research with radioactive material is performed. The RNC has facilities for all kinds of chemical, biological and medical research with Radionuclides at Type-2-level.

SMI PHARMACEUTICAL FORWARD PLANNER 2013 JANUARY Biomarkers Summit 16 – 17 January 2013, London Social Media in the Pharma Industry 23 – 24 January 2013, London Quality by Design 23 – 24 January 2013, London Pre-Filled Syringes 28 – 29 January 2013, London Pharmaceutical Microbiology 30 – 31 January 2013, London FEBRUARY Parallel Trade 6 – 7 February 2013, London Advances and Progress in Drug Design 18 – 19 February 2013, London Lyophilisation - Freeze Drying in Pharmaceuticals and Biopharmaceuticals 25 – 26 February 2013, London MARCH Superbugs & Superdrugs - A Focus on Antibacterials 4 – 5 March 2013, London Imaging in Cancer Drug Development 13 – 14 March 2013, London Controlled Release 18 – 19 March 2013, London Paediatric Clinical Trials 20 – 21 March 2013, London APRIL Adaptive Designs 8 – 9 April 2013, London Asthma & COPD 15 – 16 April 2013, London Pharmaceutical Portfolio & Lifecycle Management 17 – 18 April 2013, London MAY Generics, Supergenerics & Patent Strategies 13 – 14 May 2013, London Pain Therapeutics 20 – 21 May 2013, London ADC Summit 20 – 21 May 2013, London Clinical Trial Logistics 22 – 23 May 2013, London JUNE RNAi & Nanotechnology 5 – 6 June 2013, London

IMAGING IN CANCER DRUG DEVELOPMENT Conference: Wednesday 13th and Thursday 14th March 2013, Copthorne Tara Hotel, London, UK

Workshop: Tuesday 12th March 2013, London

4 WAYS TO REGISTER FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711

www.cancer-imaging.com POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

EARLY BIRD □ DISCOUNT □

Book by 7th December to receive a £300 off the conference price Book by 18th January to receive a £200 off the conference price

CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee

Unique Reference Number Our Reference

LVP-060

Total

□ Conference & Workshop

£2098.00

+ VAT

£2517.60

□ Conference only

£1499.00

+ VAT

£1798.80

□ Workshop only

£599.00

+ VAT

£718.80

£999.00

+ VAT

£1198.80

PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees

DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title:

Forename:

GROUP DISCOUNTS AVAILABLE

Surname: The conference fee includes refreshments, lunch, conference papers and access

Job Title:

to the Document Portal containing all of the presentations.

Department/Division: Company/Organisation: Email:

VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR

Company VAT Number:

□ Please contact me to book my hotel

Address:

Alternatively call us on +44 (0) 870 9090 711, email: [email protected] or fax +44 (0) 870 9090 712 Town/City: Post/Zip Code:

Country:

Direct Tel:

Direct Fax:

DOCUMENTATION

Mobile: Switchboard: Signature:

Date:

I agree to be bound by SMi's Terms and Conditions of Booking.

I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations – paper copy £499.00 £499.00 (or only £300 if ordered with the Document Portal)

ACCOUNTS DEPT Title:

PAYMENT

Forename:

Surname:

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-060 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

Email: Address (if different from above):

□ UK BACS □ Wire Transfer

Town/City: Post/Zip Code:

Country:

Direct Tel:

Direct Fax:

□ Cheque □ Credit Card

Sort Code 300009, Account 00936418 Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 We can only accept Sterling cheques drawn on a UK bank. □ Visa □ MasterCard □ American Express

All credit card payments will be subject to standard credit card charges.

Terms and Conditions of Booking Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

□□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Card No:

Cardholder’s Name: Signature:

Date:

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above):

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager [email protected] or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document Portal and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: ______________________________________

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at [email protected]